BioCentury

7:00 AM GMT, Apr 16, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

Neurotune: Linking brain and brawn

As the population ages, sarcopenia - loss of skeletal muscle mass - is an increasingly important unaddressed problem. Neurotune AG thinks neurotrypsin could serve both as a biomarker and therapeutic target for the disease and that its neurotrypsin inhibitors also may work in stroke, brain trauma and schizophrenia.

Neurotune CSO Peter Sonderegger led the group

Read the full 546 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.